Adapthealth Corp (AHCO) Peer Comparison

$6.49

$0.07 (1.09%)

As on 04-Sep-2026 16:15EDT

Market cap

$772 Mln

Revenue (TTM)

$3,009 Mln

P/E Ratio

--

P/B Ratio

0.6

Div. Yield

0 %

Edit

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	772	12,650	10,638	9,762	9,948
Revenue ($ Mln)	3,009	1,505	613	2,589	785
Net Profit ($ Mln)	-228.23	160.59	-188.05	222.40	41.54
Net Margin (%)	-7.58	10.67	-30.68	8.59	5.29
RoE (%)	-16.09	10.86	-28.10	3.04	1.97
Price to Earnings	--	79.29	--	44.47	251.81
Price-To-Book	0.56	8.31	15.27	1.36	4.86

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	3,009.03	1,504.87	612.84	2,589.30	785.10
Cost of Revenue	2,696.93	483.98	127.96	1,245.50	384.30
Gross Profit	568.56	942.44	393.22	1,343.60	347.62
Operating Expenses	321.54	833.56	565.37	1,108.90	335.50
Operating Profit (EBIT)	-9.44	187.34	-80.49	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-247.08	203.83	-192.83	350.40	52.15
Provision for Tax	-12.32	43.24	-4.79	128.00	10.61
Profit after Tax (Net Income)	-228.23	160.59	-188.05	222.40	41.54
Minority Interest	-4.85	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	1,378.47	1,530.77	682.49	7,173.90	2,112.03
Minority Interest	-4.85	0.00	0.00	0.00	0.00
Non-Current Liabilities	2,245.40	210.18	135.71	2,116.80	705.49
Current Liabilities	709.21	233.78	102.33	961.30	132.66
Total Liabilities	4,316.58	1,826.52	893.49	10,576.50	2,949.70

Assets ($ Mln)

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	3,543.43	630.60	404.74	7,231.50	1,749.63
Current Assets	797.48	1,344.12	515.78	3,020.50	1,200.55
Total Assets	4,316.58	1,826.52	893.49	10,576.50	2,949.70
Total Debt*	2,065.09	212.71	102.84	1,203.70	690.94
Net Current Assets	88.26	1,110.35	413.45	2,059.20	1,067.90

Cashflow ($ Mln)

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	601.77	238.66	-46.34	532.20	117.42
Cash Flow from Investing Activities	-303.19	-404.59	-77.61	-189.70	-298.47
Cash from Financing Activities	-302.19	26.53	11.89	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-1.99	11.76	-22.53	8.98	1.79
ROE (%)	-16.09	10.86	-28.10	3.04	1.97
ROA (%)	-4.55	7.95	-18.00	2.02	1.36
EBIT Margin (%)	-4.75	13.63	-30.58	-5.99	9.87
Net Margin (%)	-7.58	10.67	-30.68	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	14.57	17.55	41.55	1.37	16.49
EBIT Growth (%)	-157.36	17.49	-116.42	-131.06	920.91
Net Profit Growth (%)	-383.21	8.72	-102.66	-30.32	400.42
EPS Growth (%)	-385.54	8.12	-96.88	-29.66	394.30
Book Value Growth (%)	-12.56	17.33	-12.65	2.19	2.16

Valuation Ratios

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-19.05	68.93	-34.59	--	189.42
Price / Book Value	0.89	8.31	15.27	--	4.40
Dividend Yield (%)	--	0.00	0.00	--	--
EV/EBITDA	6.25	55.45	-73.80	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	1.36	0.00	0.00	0.11	0.26
Short term debt to equity ratio	0.05	0.01	0.00	0.06	0.01
Current Ratio	1.12	5.75	5.04	3.14	9.05
Quick Ratio	0.98	3.86	4.46	2.33	7.64
Interest Coverage	-1.43	157.91	-38.31	8.18	3.36

Operating Efficiency Ratios

	Adapthealth Corp (AHCO)	Penumbra (PEN)	Glaukos Corp (GKOS)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	12.97	12.65	22.67	17.06	20.09
Asset Turnover	0.60	0.74	0.59	0.24	0.26
Receivable days	43.84	46.54	60.95	65.39	72.41
Inventory Days	19.86	331.92	193.84	221.09	146.53
Payable days	43.47	26.16	60.19	37.02	29.05
Cash Conversion Cycle	20.24	352.30	194.60	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly